ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

NetDania - New 12 months High: ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

08 Mar 2024 08:54:04 By NetDania Notify

NetDania - New 12 months High: ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

07 Mar 2024 08:53:27 By NetDania Notify

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

16 May 2022 16:00:00 By Nasdaq GlobeNewswire

Adaptimmune Reports First Quarter Financial Results and Business Update

09 May 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

04 May 2022 07:00:00 By Nasdaq GlobeNewswire

Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

28 Apr 2022 15:30:00 By Nasdaq GlobeNewswire

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors

08 Apr 2022 12:00:00 By Nasdaq GlobeNewswire

Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022

08 Mar 2022 11:35:58 By Nasdaq GlobeNewswire

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

26 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS

11 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Adaptimmune Reports Third Quarter Financial Results and Business Update

04 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021

21 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

05 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial

13 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

07 Sep 2021 06:00:02 By Nasdaq GlobeNewswire

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

05 Sep 2021 05:15:00 By Nasdaq GlobeNewswire

Adaptimmune Reports Second Quarter Financial Results and Business Update

09 Aug 2021 15:00:00 By Nasdaq GlobeNewswire

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

28 Jul 2021 07:11:31 By Nasdaq GlobeNewswire

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

19 May 2021 16:00:00 By Nasdaq GlobeNewswire